2. WHO Director-General’s opening remarks at the media briefing on COVID-19 –11 March 2020. World Health Organization, 2019. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.

3. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). ArcGIS. Johns Hopkins University, 2020. https://gisanddata.maps.arcgis.com/ apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.

4. Livingston E., Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 2020; 323(14): 1335. doi: 10.1001/jama.2020.4344

5. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases COVID-19-China. CCDC Weekly 2020; (2): 1–10. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8- db1a8f51

6. Tezer H., Bedir Demirdağ T. Novel coronavirus disease (COVID-19) in children. Turk. J. Med. Sci. 2020; 50(SI-1): 592–603. doi: 10.3906/sag-2004-174

7. Yasuhara J., Kuno T., Takagi H., Sumitomo N. Clinical characteristics of COVID-19 in children: A systematic review. Pediatr. Pulmonol. 2020 ; 55(10): 2565–75. doi: 10.1002/ppul.24991

8. Горелов А.В., Николаева С.В., Акимкин В.Г. Новая коронавирусная инфекция COVID-19: особенности течения у детей в Российской Федерации. Педиатрия. Журнал им. Г.Н. Сперанского 2020; 99 (6): 57–62. doi: 10.24110/0031-403X-2020-99-6-57-62

Gorelov A.V., Nikolaeva S.V., Akimkin V.G.

9. Краснова Е.И., Карпович Г.С., Комиссарова Т.В., Извекова И.Я., Михайленко М.А., Серова Ю.С., Шестаков А.Е. Особенности течения COVID-19 у детей различных возрастных групп. Педиатрия. Журнал им. Г.Н. Сперанского 2020; 99(6): 141–7. doi: 10.24110/0031-403X-2020-99-6-141-147

Krasnova E.I., Karpovich G.S., Komissarova T.V., Izvekova I.I., Mihajlenko M.A., Serova Yu.S., Shestakov A.E.

10. Radia T., Williams N., Agrawal P., Harman K., Weale J., Cook J., Gupta A. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr. Respir. Rev. 2021; 38(35): 51–7. doi: 10.1016/j.prrv.2020.08.001

11. Nakra N.A., Blumberg D.A., Herrera-Guerra A., Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel) 2020; 7 (7): 69. doi: 10.3390/children7070069

12. Fujimaru T., Ito S., Masuda H., Oana S., Kamei K., Ishiguro A., Kato H., Abe J. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange. Cytokine 2014; 70 (2): 156–60. doi: 10.1016/j.cyto.2014.07.003

13. Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N. et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host. Microbe 2020; 27(6): 992–1000.e3. doi: 10.1016/j.chom.2020.04.009

14. Galeotti C., Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat. Rev. Rheumatol. 2020; 16 (8): 413–14. doi: 10.1038/s41584-020-0448-7

15. Askanase A.D., Khalili L., Buyon J.P. Thoughts on COVID-19 and autoimmune diseases. Lupus Sci Med. 2020; 7 (1): e000396. doi: 10.1136/lupus-2020-000396

16. Cañas C.A. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med. Hypotheses 2020; 145: 110345. doi: 10.1016/j.mehy.2020.110345

17. Liu Y., Sawalha A.H., Lu Q. COVID-19 and autoimmune diseases. Curr. Opin. Rheumatol. 2020; Publish Ahead of Print. doi: 10.1097/BOR.0000000000000776

18. Lazarian G., Quinquenel A., Bellal M., Siavellis J., Jacquy C., Re D. et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br. J. Haematol. 2020; 190 (1): 29–31. doi: 10.1111/bjh.16794

19. Zulfiqar A.-A., Lorenzo-Villalba N., Hassler P., Andrès E. Immune thrombocytopenic purpura in a patient with COVID-19. N. Engl. J. Med. 2020; 382: e43. doi: 10.1056/NEJMc2010472

20. Dalakas M.C. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol. Neuroimmunol. Neuroinflamm. 2020; 7 (5): e781. doi: 10.1212/NXI.0000000000000781

21. Rojas M., Restrepo-Jiménez P., Monsalve D.M., Pacheco Y., Acosta-Ampudia Y., Ramírez-Santana C. et al. Molecular mimicry and autoimmunity. J. Autoimmun. 2018; 95: 100–23. doi: 10.1016/j.jaut.2018.10.012

22. Pacheco Y., Acosta-Ampudia Y., Monsalve D.M., Chang C., Gershwin J.-M. Anaya Bystander activation and autoimmunity. J. Autoimmun. 2019: 103. 102301. doi: 10.1016/j.jaut.2019.06.012

23. Lucchese G., Flöel A. Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons. Autoimmun. Rev. 2020; 19 (7): 102556. doi: 10.1016/j.autrev.2020.102556

24. Kanduc D., Shoenfeld Y. On the molecular determinants of the SARS-CoV-2 attack. Clin. Immunol. 2020; 215: 108426. doi: 10.1016/ j.clim.2020.108426

25. Vojdani A., Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol. 2020; 217: 108480. doi: 10.1016/j.clim.2020.108480